english – The Buzz Magazine https://thebuzzmagazine.ma The Buzz Magazine Tue, 01 Dec 2020 15:31:54 +0000 ar hourly 1 https://wordpress.org/?v=5.6.4 Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA https://thebuzzmagazine.ma/hikma-pharmaceuticals-and-sesen-bio-announce-exclusive-partnership-to-commercialise-vicineum-in-mena/ https://thebuzzmagazine.ma/hikma-pharmaceuticals-and-sesen-bio-announce-exclusive-partnership-to-commercialise-vicineum-in-mena/#respond Tue, 01 Dec 2020 15:31:45 +0000 https://thebuzzmagazine.ma/?p=19545 Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA Amman, December 1, 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced an exclusive licensing and distribution agreement with Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer. The licensing agreement provides […]

The post Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA appeared first on The Buzz Magazine.

]]>
Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA
Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA


Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA

Amman, December 1, 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced an exclusive licensing and distribution agreement with Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer.

The licensing agreement provides Hikma with exclusive rights to commercialise and distribute Vicineum in the MENA region for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) and other types of cancer.

Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive NMIBC.

In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review.

“At Hikma, we believe that partnerships with innovative pharma companies are a key contributor to the success of our business.

We are very pleased to enter into an exclusive partnership with Sesen given their expertise in NMIBC and the strong clinical profile of Vicineum,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA.

“As a company whose mission is to put better health within reach every day, we regard being the partner of choice to Sesen in MENA as a key collaboration that augments Hikma’s biotechnology and oncology portfolio to deliver on our strategy of bringing innovative products to patients in the region.

Vicineum™ – our first innovative fusion protein – is a highly differentiated product candidate and is positioned to make a meaningful impact on the lives of bladder cancer patients.” 

“Sesen is committed to saving and improving the lives of patients, and Hikma is an ideal partner to deliver Vicineum to patients with NMIBC in the MENA region,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

“As we continue to work toward regulatory approval in the US and Europe, we also continue to execute partnerships outside of the US as part of our mission to deliver this important medicine to patients around the world.

Hikma has strong expertise in commercialising innovative products in the MENA region and and a successful track record of serving patients world-wide.

This partnership represents a further step in realizing the significant global opportunity for Vicineum.”

Under the terms of the agreement, Sesen Bio granted Hikma an exclusive license to register and commercialise Vicineum in all 19 MENA markets in an arrangement anticipated to deliver equal value share to both parties. 

Financial terms of the agreement are confidential and include an upfront payment to Sesen Bio, sales related milestone payments and royalties on net sales in the region for the term of the agreement.

Vicineum™

Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive NMIBC. In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review.

Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.

Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached until it is internalized by the cancer cell, which is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety.

In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells. Sesen Bio is currently conducting the Phase 3 VISTA trial, designed to support the registration of Vicineum for the treatment of high-risk NMIBC in patients who have previously received a minimum of two courses of bacillus Calmette-Guérin (BCG) and whose disease is now BCG-unresponsive.

Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors. The activity of Vicineum in BCG-unresponsive NMIBC is also being explored at the US National Cancer Institute in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab.

About Non-Muscle Invasive Bladder Cancer

Bladder cancer is the sixth most commonly diagnosed cancer in the United States, and approximately 80 percent of patients have non-muscle invasive bladder cancer (NMIBC). In NMIBC, cancer cells are in the lining of the bladder or have grown into the lumen of the bladder but have not spread into muscle or other tissue. NMIBC primarily affects men and is associated with carcinogen exposure.

Initial treatment includes surgical resection; however, there is a high rate of recurrence and more than 60 percent of all patients diagnosed with NMIBC will receive bacillus Calmette-Guérin (BCG) immunotherapy.

While BCG is effective in many patients, challenges with tolerability have been observed and many patients will experience recurrence of disease.

If BCG is not effective or a patient can longer receive BCG, the recommended option for treatment is radical cystectomy, the complete removal of the bladder.

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody’s)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them.

Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives.

We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities.

We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.

The Company’s lead program, Vicineum™, also known as VB4-845, is currently in a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review.

Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.

For more information, please visit the company’s website at www.sesenbio.com

The post Hikma Pharmaceuticals and Sesen Bio announce exclusive partnership to commercialise Vicineum™ in MENA appeared first on The Buzz Magazine.

]]>
https://thebuzzmagazine.ma/hikma-pharmaceuticals-and-sesen-bio-announce-exclusive-partnership-to-commercialise-vicineum-in-mena/feed/ 0
Is Kylie Jenner Dating Fai Khadra? Apparently not https://thebuzzmagazine.ma/is-kylie-jenner-dating-fai-khadra-apparently-not/ https://thebuzzmagazine.ma/is-kylie-jenner-dating-fai-khadra-apparently-not/#respond Sun, 30 Aug 2020 13:28:17 +0000 https://thebuzzmagazine.ma/?p=14218 Kylie Jenner traveled to Paris with her friend Fai Khadra during a pandemic. She posted a few maskless photos of herself on Instagram. In a couple of them, she and Khadra were looking quite cozy, but TMZ says that the two are not dating. TMZ’s sources said that despite what these photos seem to convey, […]

The post Is Kylie Jenner Dating Fai Khadra? Apparently not appeared first on The Buzz Magazine.

]]>
Is Kylie Jenner Dating Fai Khadra? Apparently not
Is Kylie Jenner Dating Fai Khadra? Apparently not

Kylie Jenner traveled to Paris with her friend Fai Khadra during a pandemic. She posted a few maskless photos of herself on Instagram. In a couple of them, she and Khadra were looking quite cozy, but TMZ says that the two are not dating.

TMZ’s sources said that despite what these photos seem to convey, Kylie and Khadra are just very good friends. Khadra also tagged along for Kylie’s trip to Utah, but source say he’s firmly in the friend zone.

IS KYLIE JENNER DATING JORDYN WOODS’ RUMORED EX-BOYFRIEND, FAI KHADRA
IS KYLIE JENNER DATING JORDYN WOODS’ RUMORED EX-BOYFRIEND, FAI KHADRA

Rumors surrounding Kendall Jenner’s relationship with NBA player Devin Booker have also been circulating. Booker is reportedly part of Kendall’s quarantine circle, and a source told TMZ that Booker and Kendall are just friends.

“Kendall and friends have a small social circle amongst the group, who have been following the same social distancing and physical distancing guidelines. Devin is a friend and is part of the small group.”

Kendall and Booker have something in common with Kylie and Khadra; they went on a road trip together to Sedona, Arizona. Yes, this is a better option than flying, but Kendall and Booker had not been quarantining together before this trip.

“They took a road trip for some much-needed air,” the source told TMZ. Last week, The Sun captured the two cuddling on the beach in Malibu, and this interaction looked far friendlier than a platonic thing.

By the way, California, where Jenner lives, has high COVID-19 numbers, and France has its highest number of cases since May.

Kylie Jenner News
Kylie Jenner News

The post Is Kylie Jenner Dating Fai Khadra? Apparently not appeared first on The Buzz Magazine.

]]>
https://thebuzzmagazine.ma/is-kylie-jenner-dating-fai-khadra-apparently-not/feed/ 0
Migrant rescue boat funded by street artist Banksy pleads with Europe to let it ashore https://thebuzzmagazine.ma/migrant-rescue-boat-funded-by-street-artist-banksy-pleads-with-europe-to-let-it-ashore/ https://thebuzzmagazine.ma/migrant-rescue-boat-funded-by-street-artist-banksy-pleads-with-europe-to-let-it-ashore/#respond Sun, 30 Aug 2020 10:36:47 +0000 https://thebuzzmagazine.ma/?p=14213 The ship has been decorated by the artist in a riff on his famous Balloon Girl artwork A hot pink refugee ship, on a secret mission in the Mediterranean, is the latest project by anonymous British street artist Banky . The artist has financed a rescue operation to bring refugees from North Africa safely to Europe […]

The post Migrant rescue boat funded by street artist Banksy pleads with Europe to let it ashore appeared first on The Buzz Magazine.

]]>

The ship has been decorated by the artist in a riff on his famous Balloon

Girl artwork

A hot pink refugee ship, on a secret mission in the Mediterranean, is the latest project by anonymous British street artist Banky .

The artist has financed a rescue operation to bring refugees from North Africa safely to Europe aboard the Louise Michel. The boat is crewed by activists who have worked in search-and-rescue missions with Sea-Watch, a German NGO that patrols the Mediterranean to rescue migrants.

The artist approached Sea-Watch captain Pia Klemp last September in the hopes of aiding their efforts.

“I’ve read about your story in the papers. You sound like a badass,” Banksy wrote to Klemp, according to the Guardian. “I am an artist from the UK and I’ve made some work about the migrant crisis, obviously I can’t keep the money. Could you use it to buy a new boat or something? Please let me know.”

The ship features an original Banksy artwork—a lifejacket-clad girl holding aloft a buoy shaped like a heart, in a take on his famous Balloon Girl image—but the artist is letting the professionals handle the search-and-rescue duties.

“Banksy won’t pretend that he knows better than us how to run a ship, and we won’t pretend to be artists,” Klemp told the Guardian.

The ship, named after the Paris Commune revolutionary, left port on August 18 from Burriana, Spain. The vessel has already rescued 89 people, including 14 women and four children.

The 10-person crew is looking to bring them ashore to the European mainland before they are detained by the Libyan coastguard, which would likely transfer them to detention camps in the war-torn nation, which has been the fate of over 7,600 migrants this year alone, according to the International Organization for Migration.

The voyage was kept a secret upon departure out of fear that press coverage would have drawn undue attention from authorities. The Louise Michel is now looking for a safe seaport where the passengers can disembark, or to transfer them to a European coastguard vessel.

The plight of refugees has been a recurring theme  in Banksy’s work, including in .several pieces skewering France’s Calais refugee camp

Just last month, the artist auctioned off a trio of found seascapes he altered to include empty lifejackets symbolizing those who have died crossing the Mediterranean, donating the proceeds of the £2.23 million ($2.95 million) sale to a Bethlehem hospital. 

The 2020 death count among refugees and migrants in the Mediterranean stands at at least 500, including 45 who died just yesterday in an explosion off the coast of Libya. It was the deadliest shipwreck in the country this year.

The post Migrant rescue boat funded by street artist Banksy pleads with Europe to let it ashore appeared first on The Buzz Magazine.

]]>
https://thebuzzmagazine.ma/migrant-rescue-boat-funded-by-street-artist-banksy-pleads-with-europe-to-let-it-ashore/feed/ 0